Jump to content

SyneuRx™ gibt bekannt, dass der orale antivirale COVID-19-Kandidat Pentarlandir® den letzten Teil der FDA-Phase-II-Tests erreicht hat


In The News

Recommended Posts

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now


×
×
  • Create New...